RECRUITING

Neurofeedback to Reduce Spontaneous Recovery of Threat Expectancy

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study tests the efficacy of a new behavioral intervention with the goal of reducing spontaneous recovery of threat expectancy in healthy adults. This real-time functional magnetic resonance imaging (fMRI) neurofeedback intervention delivers feedback based on a functional connection between the prefrontal cortex and the hippocampus.

Official Title

Reducing Spontaneous Recovery Using Functional Connectivity Based Real-time Functional Magnetic Resonance Imaging Neurofeedback Targeting the Memory Control Network

Quick Facts

Study Start:2025-07-17
Study Completion:2028-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07122739

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults aged 18-50
  2. * No history of psychiatric disorders or neurological disorders affecting the central nervous system.
  3. * Are not currently taking psychoactive medication or drugs of abuse.
  4. * Must be eligible to enter an MRI (i.e., no permanent metal or medical implants)
  5. * Normal color vision
  6. * Right-handed
  7. * Full reading and writing English comprehension
  8. * Must exhibit spontaneous recovery behavior as determined by an experimenter in a prescreening experimental session
  9. * Must be able to provide informed consent
  1. * Pregnancy (female participants)
  2. * Outside of age range
  3. * History of psychiatric or neurological disease
  4. * Currently taking psychoactive medication or drugs of abuse
  5. * Color blindness
  6. * Primary left-handedness
  7. * Less than full reading and writing English comprehension
  8. * Do not exhibit spontaneous recovery behavior as determined by an experimenter in a prescreening experimental session
  9. * Refusing to provide informed consent

Contacts and Locations

Study Contact

Augustin C. Hennings, Ph.D.
CONTACT
609-258-5032
gus.hennings@princeton.edu

Principal Investigator

Kenneth A. Norman, Ph.D.
PRINCIPAL_INVESTIGATOR
Princeton University

Study Locations (Sites)

Princeton Neuroscience Institute
Princeton, New Jersey, 08540
United States

Collaborators and Investigators

Sponsor: Trustees of Princeton University

  • Kenneth A. Norman, Ph.D., PRINCIPAL_INVESTIGATOR, Princeton University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-17
Study Completion Date2028-06

Study Record Updates

Study Start Date2025-07-17
Study Completion Date2028-06

Terms related to this study

Additional Relevant MeSH Terms

  • Healthy